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In PNAS, Jurado et al. (1) describe an un-
expected mechanism of action of a new
class of HIV type 1 (HIV-1) integrase
(IN) inhibitors. Several years ago it was
discovered that the HIV-1 IN was tar-
geted to sites in chromatin by the host
protein lens epithelium-derived growth
factor (LEDGF)/p75 (2). The site of inter-
action between IN and LEDGF/p75 was
defined, and inhibitors to block that in-
teraction were sought and identified.
In PNAS, Jurado et al. (1) show that al-
though these inhibitors (termed Allosteric
IN inhibitors, or ALLINIs) have some po-
tency to block steps involved in integration,
their most dramatic effect is to cause the
virus particle to assemble into a non-
infectious structure.
The IN protein contains three structural
domains: the N-terminal domain (NTD; a
series of α-helices and a zinc-binding motif),
the central catalytic core domain (CCD), and
the C-terminal domain (structurally similar
to a SH3 β-barrel fold) (3). The CCD has
a structure that makes it a member of an
ancient family of polynucleotide transferases
(also seen in the RNase H domain at the C
terminus of HIV-1 reverse transcriptase),
with a D,DX35E catalytic triad comprising
the active site by coordinating two essential
Mg2+ ions. IN must complete two enzymatic
steps to insert viral DNA into the host cell
genome. In the first reaction, IN cleaves the
two terminal nucleotides at the 3′ ends of
the newly synthesized linear viral DNA to
create the 3′-OH nucleophiles that will be
used in the second reaction. In the second
reaction, the strand transfer, IN uses the
new 3′ ends of viral DNA to break phos-
phodiester bonds in the host DNA, and
simultaneously insert viral DNA.
The prototype foamy virus intasome
(the IN/DNA nucleoprotein complex ca-
pable of integration) currently provides the
example for retroviral integration machin-
ery (4), and this has also allowed modeling
of the HIV-1 intasome (5). Each intasome
consists of a dimer of IN dimers in com-
plex with the two viral DNA ends (Fig.
1A). For each individual dimer, only one
CCD engages the DNA substrate; the role
of the monomers that do not engage the
DNA (gray in Fig. 1A) is likely a support
function. LEDGF/p75 binds the IN dimer
at an interface between the CCDs (6), al-
though the NTD is necessary for high-af-
finity interactions (2). In the context of
integration, this interaction must occur
subsequent to assembly of the intasome
and 3′ end processing of viral DNA by
IN. It was this interaction that these com-
pounds were designed to disrupt by bind-
ing to the LEDGF/p75 interface in IN.
Fig. 1. Multimodal mechanisms of ALLINI action. (A) Model of the HIV-1 intasome bound to the INSTI Raltegravir
(yellow) and ALLINI BI-D (red). The inner monomer subunits (blue/green) bind viral DNA and are catalytically active. The
catalytic core domains of the outer monomers (gray) provide structural support; the N- and C-terminal domains of the
outer monomers have not been resolved by X-ray crystallography. INSTIs bind the active site of the inner monomers,
displacing the reactive 3′-OH group of the terminal deoxyadenosine (black). ALLINIs locate to the LEDGF/p75 binding
site (cyan) found at a dimerization interface. (B) Schematic demonstrating the three mechanisms of ALLINI action (red
arrows). ALLINIs can promote early dimerization and stabilization of integrase multimers, blocking association with
viral DNA. ALLINIs also compete with LEDGF/p75 for binding to assembled intasomes, reducing the efficiency of
chromatin-association and strand transfer/integration. Finally, virus particles assembled in the presence of ALLINIs
result in improper virion maturation, rendering nascent particles noninfectious.
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ALLINIs are preceded by an earlier class of
IN inhibitors. Screens targeting intasomes
with 3′ end-processed DNA led to the iden-
tification of a class of inhibitors that specifi-
cally blocks the strand transfer reaction
(INSTIs) (7). These inhibitors include nega-
tively charged or polar groups that allow the
inhibitor to align on the Mg2+ ions at the
active site and displace the 3′ terminal deox-
yadenosine in viral DNA critical to the
strand transfer reaction (4). Thus, the
ALLINIs are directed at an entirely new
target on the IN structure.
Dominant-negative forms of LEDGF/p75
can act as inhibitors of integration (8),
validating its relevance as a target. The
original small-molecule inhibitors of the
IN-LEDGF/p75 interaction were discov-
ered by pharmacophore modeling (9).
ALLINIs were expected to inhibit integra-
tion by blocking the interaction with
chromatin-bound LEDGF/p75, which they
do (9) (Fig. 1B). However, the actual breadth
of viral activities affected includes two
additional processes. ALLINIs also pro-
mote the premature assembly and stabili-
zation of IN dimers in the absence of viral
DNA, indirectly blocking the two down-
stream enzymatic reactions by preventing
association with the viral DNA (9–12)
(Fig. 1B). In addition, ALLINIs surpris-
ingly also inhibit the production of infec-
tious virus particles (i.e., steps that occur
after integration and expression of viral
RNA and proteins) (Fig. 1B). This phe-
nomenon was first described by Christ
et al. (10), but is examined in greater detail
by Jurado et al. (1).
The outline of the assembly/maturation
process that results in infectious virus par-
ticles is well understood, although many
important details are still unknown (13).
The viral Gag precursor protein contains
the structural proteins of the virion: matrix
(MA), capsid (CA), nucleocapsid (NC), and
p6. About 5% of the time Gag is linked to
sequences encoded in an alternate reading
frame to create a Gag-Pro-Pol fusion pro-
tein, where the Gag structural proteins are
now linked to the enzymes needed for viral
replication: protease (encoded by the pro
gene), and reverse transcriptase and IN
(encoded in the pol gene). Upon dimeriza-
tion, protease activates and releases all of
the other viral proteins in a sequence of
proteolytic processing events that facilitates
the assembly of an infectious virion.
ALLINIs do not inhibit the release of
virus particles (1, 10) or the processing of
viral proteins (1), which suggests they do
not initiate premature dimerization of the
Gag-Pro-Pol precursors, because prema-
ture activation of protease manifests as
impaired particle production (14). Pre-
sumably the effect of ALLINIs is still at
the level of IN, (as shown by resistance
mutations), by inappropriately stabilizing
IN dimers in the assembly process. Al-
though not discussed directly in Jurado
et al.’s report (1), it is tempting to suggest
a specific defect in the assembly process.
Thin-section electron microscopy of virus
reveals two major processes in virion mat-
uration: the condensation of the RNA with
NC, (which, after staining, is electron
dense), and the formation of the CA capsid
cone, (which stains poorly and appears
more wispy). In a properly assembled vi-
rion, the capsid forms around the con-
densed nucleoprotein core. The virions
shown in Jurado et al. (1) appear to have
dissociated these two processes, with ap-
parent capsid formation squeezing the con-
densed nucleoprotein core to the side.
The assembly/maturation pathway is
itself a potentially important target for
inhibitors. Each virus must create a com-
plex structure to exit the cell, and then
successfully undergo reorganization after
budding from the cell to generate a capsid
structure that will allow subsequent DNA
synthesis, nuclear transport, and integra-
tion to occur upon entry of a new cell.
Perturbations of this structure can easily
affect multiple steps. The development of
the drug bevirimat, which inhibits cleavage
at the C-terminal end of CA, represents
a proof-of-concept for using the assembly/
maturation pathway as a target (15). Simi-
larly, a number of small molecules, such as
CAP-1 (16) or CAI (17), can bind to the N-
or C-terminal domain of CA, respectively,
where they likely interfere with CA–CA
interactions necessary for stabilizing the
cone structure (18, 19). In our own work
we have found that using a genetic trick to
inhibit cleavage at theMA-CA site by as little
at 10% results in complete loss of virion in-
fectivity, presumably by tethering the assem-
bling capsid to the membrane through
residual MA-CA fusion proteins (20). Fur-
thermore, a truncated version of another IN-
binding protein, INI1/hSNF5, transdomi-
nantly interferes with particle production
(21), possibly by facilitating the early pro-
cessing of the Gag polyprotein. BI-D, the
ALLINI of note from Jurado et al. (1), joins
a growing list of assembly/maturation inhib-
itors that target this complex pathway, a
pathway where complete surprises, like the
ability of allosteric inhibitors of IN to cre-
ate aberrant virions, still await.
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